Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight ...

Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed throughout ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

It works by activating receptors of the GLP-1 hormone while blocking receptors of the GIP hormone. Meanwhile, Eli Lilly and Company’s weight-loss drug Zepbound activates both receptors.

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed ...